Anti-interleukin-17 therapies for moderate/severe psoriasis in clinical practice: effectiveness, safety and association with clinical patient factors.

Estela García-MartínR M Romero-JiménezOfelia Baniandrés-RodríguezVicente Escudero-VilaplanaJuana Benedí-GonzálezPaloma Morales de Los Ríos LunaAna Herranz-AlonsoMaría Sanjurjo-Sáez

Published in: European journal of hospital pharmacy : science and practice (2023)

Anti-IL-17 agents constitute an effective treatment for patients with moderate/severe plaque psoriasis and for longer. Dose reductions were associated with fewer lines of treatment, younger patients and absence of concomitant pathologies. ADR were minor and similar among the anti-IL-17.

Keyphrases

end stage renal disease
high intensity
randomized controlled trial
early onset
emergency department
ejection fraction
peritoneal dialysis
chronic kidney disease
prognostic factors
atopic dermatitis
combination therapy